Author: zakaria
-

M-Coalition launch a new guide: Key Population Engagement in Global Fund Country Dialogue CCMs and the 2017-‐2019 funding cycle
Source : M-Colaition This resource guide is designed to assist civil society organizations in understanding how to access funding from the Global Fund (GF) and effectively engage in country dialogue through all the key stages. In 2014, the Global Fund’s New Funding Model (NFM) was launched. Inclusion of civil society and key affected populations (KAP)…
-

Time is Ticking! Submission Dates for Global Fund Funding Requests
Know your timeline! Submission dates for MENA Global Fund Funding Requests : Greetings from the Regional Communication and Coordination Platform for Middle East & North Africa, hosted by ITPC-MENA. We are preparing a newsletter and series of briefs for you in the coming months, but wanted to make sure you had the following information right…
-

UN High-Level Panel On Access To Medicines Takes Next Step At Human Rights Council
by Catherine Saez, Intellectual Property Watch: The United Nations Human Rights Council held a panel discussion yesterday to exchange views on good practices and key challenges relevant to access to medicines. The panel gave a large part of the discussion to the recent report of the United Nations Secretary General’s High-Level Panel on Access to…
-

Amendment of the TRIPS Agreement
WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after acceptance of the Protocol amending the TRIPS Agreement by two thirds of the WTO’s members.…
-

Youth Toolkit for the High Level Meeting on HIV/AIDS 2016
The youth toolkit for the High Level Meeting on HIV/AIDS (HLM) 2016 is developed by the PACT, a global coalition of youth organizations working collaboratively in the HIV response towards ensuring the health, well-being and human rights of all young people. The toolkit provides information about the HLM including what happens before, during and after…
-

Morocco: Creation of a collective for t the right to health in the framework of the negotiations of the EU ALECA
At a time when the Kingdom of Morocco and the European Union are preparing to resume negotiations on the “comprehensive and thorough free trade agreement” (FTAA), Moroccan civil society unites to bell Alarm about ALECA’s danger of access to generics in our country. A collective for the preservation of the right to health in Morocco in…
-

African Treatment Advocates Call on ViiV Healthcare to Unlock Access to Dolutegravir for North Africa Now
Harare, December 1st, 2015 Today, at the International Conference on AIDS and STIs in Africa (ICASA), treatment advocates and activists from all over Africa united to urge ViiV Healthcare to allow affordable access to an essential drug in four North African countries. A voluntary license from Viiv Healthcare will enable all other countries in Africa…
-

Building Capacity on Intellectual Property, Free Trade Agreement and Access to Medicines Workshop
ATL MST – ITPC MENA WORKSHOP TUNISIA 16, 17 & 18 NOVEMBER 2015 One of the most pressing issues in the 21st century is the lack of availability of essential medicines to poor patients in underdeveloped and developing countries. The problem is attributed to the existing Intellectual Property Rights (IPR) regimes, which were not aligned…
-

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco
According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered by inadequate and costly treatments. The standard treatment involved a combination of pegylated interferon and…
-

Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection
The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to Tunisian patients. “For months, thousands of patients have been desperately waiting for access to sofosbuvir.…